Preclinical studies in cell culture and mouse model systems have shown that LRP1 may decrease the aggressiveness of cancer cells by down-regulating the cell-surface abundance of urokinase-type plasminogen activator receptor (uPAR), by internalizing metalloproteinases (MMPs), and by activating cell-signaling pathways that counteract β-catenin-signaling [10–13]. The gene discussed is LRP1; the disease is cancer.